How Patient Journey Analytics Improves Drug Commercialization
A drug's clinical trial data tells you how it performs under ideal conditions. It doesn't tell you where your patients actually are, why they're taking three years to get diagnosed, which physicians a ...
Clinical Differentiation Is No Longer Enough: How “Access Differentiation” Is Becoming the Real Moat
A therapy can post best-in-class trial data and still stall at launch. Not because the science was wrong, but because nobody could tell a payer what happens after the trial ends, when the drug meets r ...
Can Premium Pricing Survive in Rare Diseases? What 2026 Signals Say
For nearly two decades, rare diseases have lived in a pricing exception zone. Small patient populations, high unmet need, limited competition, and outcomes that could genuinely change a patient's life ...